There may be other solutions in the pipeline but moving through the pipeline may take several years. The experience of NNLX is a good example. If NNLX is approved by the appropriate government agencies by the end of the year they should be the BEST choice for diagnosis of Anthrax, MRSA, GSB, E-Coli and several other strains of organisms for at least two or three years that it will take NEW competition to move through the RED TAPE to make it to market. It looks like NNLX will have a two or three period to become dominant in the marketplace. The combined market the NNLX technologies cover is probably anywhere from $2 Billion to $30 Billion in the World markets. The USA alone is probably worth up to $5 Billion. Just W.A.Gs on my part but probably toward the conservative side. Even a ten percent capture of the USA market would put NNLX share price into the double digits.